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Background: The definitive indicator of Alzheimer’s disease (AD) pathology is the profuse accumulation of
amyloid-ß (Aß) within the brain. Various in vitro and cell-based models have been proposed for high throughput
drug screening for potential therapeutic benefit in diseases of protein misfolding. Caenorhabditis elegans offers a
convenient in vivo system for examination of Aß accumulation and toxicity in a complex multicellular
organism. Ease of culturing and a short life cycle make this animal model well suited to rapid screening of
candidate compounds.
Results: We have generated a new transgenic strain of C. elegans that expresses full length Aß1-42. This strain differs
from existing Aß models that predominantly express amino-truncated Aß3-42. The Aß1-42 is expressed in body wall
muscle cells, where it oligomerizes, aggregates and results in severe, and fully penetrant, age progressive-paralysis.
The in vivo accumulation of Aß1-42 also stains positive for amyloid dyes, consistent with in vivo fibril formation. The
utility of this model for identification of potential protective compounds was examined using the investigational
Alzheimer’s therapeutic PBT2, shown to be neuroprotective in mouse models of AD and significantly improve
cognition in AD patients. We observed that treatment with PBT2 provided rapid and significant protection against
the Aß-induced toxicity in C. elegans.
Conclusion: This C. elegans model of full length Aß1-42 expression can now be adopted for use in screens to
rapidly identify and assist in development of potential therapeutics and to study underlying toxic
mechanism(s) of Aß.
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One barrier to the efficiency of drug discovery efforts in
the area of Alzheimer’s disease (AD) therapeutics is the
time and labour intensive nature of animal studies using
transgenic mice. Cell based models for high throughput
screening of candidate drugs have been proposed to at-
tempt to bridge the gap between cell-free assays and
whole animal studies. Caenorhabditis elegans offers an
efficient in vivo system in which to examine the toxic* Correspondence: gmccoll@unimelb.edu.au
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reproduction in any medium, provided the oroutcomes of over-expression of proteins and peptides
that are prone to pathological misfolding [1]. C. elegans
can be further used as a cost-effective platform for dis-
covering compounds that protect against the toxicity-
associated with these misfolded proteins. Simple animal
models, like C. elegans, do not need to recapitulate all
pathological aspects of the respective diseases being
modelled to be of use. Indeed, the simplicity of this
model may be advantageous; the potentially confounding
behavioural and cognitive responses typical of the higher
vertebrate are absent. Instead, rapid and clear toxic phe-
notypes may be preferable for screening strategies, facili-
tating identification of structure-activity relationships.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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elegans allow it to be used in ways that are time and
cost-prohibitive in vertebrate systems. As such C. elegans
represents a complementary tool in drug discovery that
may be employed before testing in vertebrate models, to
expedite development of new therapeutics.
In order for this model to be useful for drug discovery
it must be predictive of efficacy in traditional vertebrate
models. In a recent large, unbiased yeast-based screen
of over 200,000 compounds in clinical use, the 8-
hydroxyquinoline chemical scaffold (8OHQ) was identi-
fied as having unique potential to reduce toxicity
associated with the aggregation of several neurodegen-
erative disease-specific proteins [2].
Within the 8OHQs, we have identified PBT2 as a
neuro-protective compound that provides rapid cogni-
tive improvement in mouse models of AD [3] and ef-
fective in improving cognition and reducing Aß in
cerebrospinal fluid in a small Phase IIa trial in AD
patients [4]. The exact mode of action of PBT2 is not
yet fully defined, however its mechanism is believed to
involve a combination of amyloid-beta (Aß) detoxifica-
tion and metal chaperone activity influencing intracellu-
lar homeostasis of biological metals (e.g. Fe, Cu and Zn)
[3,5]. Here we describe a C. elegans model of AD that
would facilitate more rapid testing of compounds to
complement the traditional vertebrate (mouse) models
for drug discovery.
The key pathological hallmark of AD is the cerebral
deposition of plaques composed of Aß peptide [6]. Aß is
produced by sequential proteolytic cleavage of the ubi-
quitously expressed type I transmembrane protein, amyl-
oid ß-protein precursor (APP). Cell and animal based
models for AD typically overexpress either APP or its
cleavage product Aß. APP is cleaved first by ß-secretase
(BACE), and then by γ-secretase, in a heteromeric com-
plex at either plasma or cellular membranes [7]. The Aß
released typically ranges from 38 to 43 amino acids in
length due to imprecise γ-secretase cleavage, with the
predominant species being 40 and 42 amino acids. The
accumulation of Aß is thought to lead to disease pro-
gression [8], however, the underlying mechanism of Aß
toxicity remains unclear.
C. elegans express an APP ortholog, APL-1 (Amyloid
Precursor-Like-1), but it lacks BACE sites. In addition,
the C. elegans genome does not appear to encode a
BACE ortholog, and to date no Aß-like peptide has been
detected in the nematode. In vivo effects of transgenic
human-Aß can therefore be examined in isolation from
APP processing, cleavage or breakdown in this model.
We determined that earlier models of human-Aß ex-
pression in C. elegans accumulate Aß3-42 due to mis-
cleavage of a synthetic signal peptide [9]. The truncated
Aß3-42 has altered in vitro biophysical characteristicscompared to full length Aß1-42, including increased
hydrophobicity and propensity to aggregate [9]. However
Aß3-42 does not significantly contribute to the Aß found
in human AD brain. A C. elegans model expressing a
more disease relevant form of Aß is required in order to
more fully exploit this system for drug discovery. Here
we describe a new C. elegans model that expresses and
accumulates full-length Aß1-42, and discuss the in vivo
phenotype. To test the predictive value of this model for
identifying protective compounds we then examined the
ability of PBT2 to protect against rapid Aß induced tox-
icity in this animal model.
Results
A C. elegans model of Aß1-42 expression
To engineer a C. elegans strain expressing full length
Aß1-42 we modified the synthetic signal peptide to be
cleaved from the transgenic Aß used in the original ex-
pression construct [10]. An extra Asp-Ala (DA) was
inserted N-terminal into the human-Aß sequence in the
expression vector pCL12(unc-54:Aß1-42) [10] (Additional
file 1: Figure S1). Predicted processing of the new prod-
uct, examined (data not shown) via SignalP 3.0 [11], sug-
gested the position of signal peptide cleavage would
yield full length Aß1-42. Based on this prediction an inte-
grated transgenic strain was engineered in C. elegans.
Transgene expression was targeted to the bodywall
muscle cells, via use of the promoter of unc-54 (which
encodes a heavy chain muscle myosin). We then con-
firmed the molecular identity of the Aß expressed in the
C. elegans strain GMC101 via complementary techni-
ques. Using immunocapture and ESI-MS we determined
the mono-isotopic molecular weight of the expressed Aß
as 4511.2586 Da with an error of 2.5 ppm (Figure 1A).
This mass is consistent with full length Aß1-42 (expected
mass 4511.2697 Da). An additional peak, shifted ~16 Da,
was observed corresponding to Aß1-42 plus a single oxy-
gen (observed mass 4527.2710 Da). SELDI-TOF-MS in-
corporating antibody capture also confirmed the expression
of Aß1-42 (Additional file 2: Figure S2). In addition, bis/
Bicine urea PAGE analysis also resolved a single species
consistent with Aß1-42 (Figure 1B). No additional truncated
Aß species were detected.
The amount of Aß1-42 expressed in this new transgenic
strain, GMC101, was then compared to that expressing
Aß3-42 (strain CL2120). Total protein was extracted via a
urea-based buffer and the relative amount of Aß was com-
pared via immuno-blot analysis densitrometry (Figure 1C-
D). An equivalent amount of Aß was detected between
strains CL2120 (Aß3-42) and GMC101 (Aß1-42).
In situ-aggregation of Aß
The cellular localization of the accumulated transgenic
Aß1-42 was then examined via immuno-histochemistry.
Figure 1 C. elegans Aß model accumulates full length Aß1– 42. A ESI-MS analysis of immuno-precipitated material from C. elegans expressing
Aß1-42. Insert shows an observed species of mono-isotopic molecular weight 4511.2586 (2.5 ppm error) and Aß1-42 plus a single oxygen (observed
mass 4527.2710). Expected mass of Aß1-42 is 4511.2697 Da. B TBS soluble lysate from C. elegans and synthetic Aβ species resolved on the basis
of hydrophobicity and immuno-detected using 4G8 as the primary antibody. Synthetic standards consist of Aβ1-42 and Aβ3-42. Included are
(4-day-old) transgenic control strain CL2122, Aβ3-42 expressing CL2120, and Aβ1-42 expressing GMC101. C Total protein extracts from C. elegans
resolved via Tricine-SDS-PAGE with immuno-detection of Aß (using 6E10) and α-tubulin. D Plot of average total Aß normalized against α-tubulin,
shown are means ± SD from n = 3 replicates.
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sections confirmed Aß localization within the bodywall
muscle cells (Figure 2), consistent with the promoter
activity of the unc-54 promoter. Fluorescence based
immuno-histochemistry also confirmed accumulation
of Aß within the bodywall muscle of unsectioned indi-
viduals (Additional file 2: Figure S2). The expressed
Aß1-42 also appears to be at least partially aggregated
as deposits stained positive for the amyloidogenic dye
Thioflavin T (ThT) (Figure 3A). Aggregated Aß1-42 could
also be detected in vivo, via staining in live animals using
the lipophillic-congo red derivative, X-34 [12] (Figure 3B).
X-34 has brighter fluorescence than ThT and detects more
Aß aggregates than ThT, as has been previously shown
[12]. Representative images of the head are shown in
Figure 3A-B, as this is a region devoid of background
fluorescence (including the GFP expressed in the intestine
as a co-marker). We noted, however, that dye-binding
aggregates are found throughout the entire length of the
adult (Additional file 3: Figure S4).Soluble Aß oligomers
Soluble oligomers of Aß have been proposed to be the
toxic form of Aß [13]. To explore this further in our C.
elegans model we used size-exclusion chromatography
under native conditions to separate soluble proteins on
the basis of size. The expressed Aß1-42 in our C. elegans
model elutes, almost exclusively, as high molecular
weight material (>100KDa). Only minor amounts of Aß
were detected that eluted in fractions consistent with
monomer. These data are consistent with the Aß form-
ing soluble oligomers and/or heteromeric complexes
with other cellular macromolecules (e.g. proteins etc).
Aß1-42 toxicity in C. elegans
Differences in transgene array copy number and the gen-
omic insertion sites of the trangenic arrays limits the
ability to directly compare phenotypes between strains.
However, we observed similar yet distinct toxic effects
from Aß1-42 versus Aß3-42. The expression of Aß1-42 had
no adverse effects on motility if adults were cultured
Figure 2 In vivo Aß1–42 accumulation. Representative immuno-histochemically stained 5 μm sections (right, middle) of paraffin embedded
adult C. elegans, showing Aß localization (= brown) in bodywall muscle cells. Shown are transverse (left, middle) and longitudinal sections though
the adult head (right) of A Transgenic control Strain CL2122, B CL2120, expressing Aß3-42, and C GMC101, expressing Aß1-42. Scale bar = 25 μm.
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(Figure 4B). In contrast, C. elegans expressing Aß3-42
show an age-dependent paralysis phenotype when cul-
tured at 20°C. However, when Aß1-42 expressing adults,
developed at 20°C, were shifted to 25°C we observed se-
vere and fully penetrant paralysis within 48 h. The par-
alysis at 25°C appeared more severe for those expressing
Aß1-42 compared to Aß3-42.
Protection against Aß-induced paralysis by an
investigational drug
The rapid paralysis from Aß1-42 expression in this C. ele-
gans strain is well suited for assessing drug effects. To
explore the utility of this nematode model of Aß toxicity
to identify protective compounds we examined the effect
of PBT2. We exposed L4 (the final larval stage) to a
range of PBT2 concentrations for 24 h prior to a shift to
25°C (Figure 5A). A dose of 10 μg/ml was found to offer
significant protection against the Aß-induced paralysis.
A protective effect of PBT2 was observed after one day
at 25°C with significantly fewer individuals exhibiting
paralysis (p < 0.001). To examine how quickly PBT2
could act we then minimized the exposure time of cul-
tures prior to the temperature shift to 25°C. When
young adults (3 days post egg lay) were exposed to PBT2
and at the same time were shifted to 25°C, significant
protection was still observed (p < 0.001, Figure 5B).
PBT2 effects on Aß toxicity therefore appear to be rapid
and are unlikely to be due to indirect effects ondevelopment. Treatment for with PBT2 for 24 h did not
affect total Aß levels (Figure 5C), or in vivo aggregated
Aß as determined by X-34 staining (data not shown).
Reduction of insulin-like signalling (ILS) in C. elegans
is known to protect against Aß toxicity [14]. To explore
whether PBT2 acts via modulation of the ILS pathway in
C. elegans we used a GFP-based reporter strain. Under
conditions of lowered ILS or stress (e.g. starvation, heat
shock, etc) DAF-16 (a FOXO transcription factor) trans-
locates from the cytoplasm to the nucleus [15]. Exposure
to PBT2 did not alter DAF-16 localization (Figure 5D),
suggesting its effects are not via modulation of ILS. We
also observed that exposure to PBT2 produced no de-
tectable induction of small heat shock proteins (data not
shown), as measured by a hsp-16.2:GFP reporter strain
[16]. This data are consistent with the protective effects
of PBT2 being derived by a mechanism other than a
generalized stress response.
Discussion
Previously, we demonstrated that the existing Aß models
in C. elegans accumulate amino truncated Aß3-42 instead
of Aß1-42 [9]. The Aß3-42 peptide has different physico-
chemical properties to Aß1-42; Aß3-42 is more hydropho-
bic and aggregates more rapidly in vitro. In human AD
brain Aß1-42 is a predominant Aß species [17], along
with additional various N- and C-terminal variants
[6,18,19]. We generated a new transgenic model of C.
elegans that accumulates full-length hu-Aß1-42 peptide.
Figure 3 In vivo Aß1–42 aggregation. Fluorescence micrographs of adult C. elegans heads. A ThT positive Aß aggregates are absent in
transgenic control strain CL2122 (top), and marked with arrow heads in CL2120, expressing Aß3-42 (middle), and GMC101, expressing
Aß1-42 (bottom). B X-34 positive Aß1-42 aggregates are seen (arrow head), CL2122 (top) and GMC101 (bottom). Scale bar = 25 μm. C. Size-excluded
soluble proteins from Aß1-42 expressing GMC101. Shown is the absorbance at 280 nm (A280) of eluted material against elution volume.
Fractions (0.75 ml) were collected from 5.25 ml onwards (marked by arrow). D Immuno-blot analysis of size-excluded fractions (F2-18) resolved via
4-12% BisTris SDS PAGE and detected with 6E10. Shown are starting material extracts from strain GMC101 (Aß1-42) and control strain CL2122.
Aß1-42 elutes predominantly in fractions F4-F5. A longer exposure (below) shows Aß also elutes in fractions consistent with lower-order
oligomers (i.e. F11-F13).
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42 we inserted two additional amino acids (-DA-) be-
tween the synthetic signal peptide and the Aß peptide
corrected the cleavage, resulting in expression of fullFigure 4 Aß1–42 accumulation causes paralysis. Age-related
paralysis phenotype in Aß3-42 and Aß1-42 expressing C. elegans.
Adults shifted to either 20°C or 25°C from the first day of adulthood
(day zero) onwards. Plotted are the mean fractions of individuals not
paralyzed ± 95% confidence intervals. Shown are control strain
CL2122 (20°C n = 60; 25°C n = 60), Aβ3-42 expressing CL2120 (20°C
n = 56; 25°C n = 60), and Aβ1-42 expressing GMC101 (20°C n = 58; 25°
C n = 0), where n = number of individuals assayed. Plot shown is
representative of 4 experiments.length Aß1-42. A similar approach was used to correct
signal peptide cleavage from Aß1-42 in an expression
construct stably transfected into COS7 cells line [20].
In our model the Aß1-42 is expressed in body wall
muscle cells, where it aggregates and results in severe
and fully penetrant age progressive-paralysis (Figure 4)
at 25°C. Anecdotal observations suggest that paralysis
from Aß1-42 is more rapid than that caused from Aß3-42
expression. Previous studies have reported a related
phenotype of reduced motility in liquid for the Aß3-42
expressing strain [21].
Disease severity of AD correlates with soluble (i.e. sol-
uble in an aqueous buffer such as phosphate- or tris-
buffered saline) but not aggregated (plaque)-Aß [22].
Several studies suggest that soluble oligomers are likely
to be the toxic form of Aß [13]. However, the extent to
which soluble Aß-oligomers exist in vivo is not clear.
Observation of Aß-oligomers in extracts resolved via so-
dium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) has questionable relevance due to Aß self-
interaction induced by SDS [23,24]. As an alternative ap-
proach we have used liquid chromatography under
Figure 5 PBT2 protects against Aß1–42 induced toxicity. Paralysis associated with Aß1-42 expression is protected by PBT2. Plotted are the
proportions of individuals not paralysed with upper and lower 95% confidence intervals. A PBT2 at 10 μg/ml was found to be most effective
when cultures were exposed to compound for 24 prior to the initiation of the assay. B PBT2 effects are very rapid, such that immediate exposure
to 10 μg/ml PBT2 suppressed Aß-induced paralysis. Control strain CL2122 (n = 74), Aß1-42 strain GMC101 (n = 73), GMC101 strain + PBT2 (n = 74),
where n = number of individuals assayed and *** p < 0.001. Plot shown is representative of 3 experiments. C Exposure to 10 μg/ml PBT2 for 24 h
did not significantly alter total Aß levels. Shown is mean ± SD quantitation via densitrometry of n = 3 immuno-blot analyses. D Exposure to PBT2
does not alter DAF-16 localization. Shown are representative epifluorescence micrographs of DAF-16: GFP cytoplasmic localization in Control and
PBT2 (10 μg/ml for 24 h) treated populations in contrast to nuclear localization in samples heat-shocked for 2 h at 35°C.
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observed that Aß1-42 in C. elegans elutes as high-
molecular-weight species (>100 KDa) consistent with
high order oligomers. Previous studies using Aß3-42
expressing C. elegans also suggest soluble Aß-oligomers
form and correlate with toxicity, rather than aggregated
Aß [14]. The precise molecular identity of the toxic Aß
species in AD brain or animal models of Aß toxicity,
and their cellular target(s) are yet to be established [25].
Treatment with ThT of C. elegans expressing Aß3-42
suppresses Aß-toxicty [26]. As ThT binds fibirils this
suggests that aggregation may influence Aß toxicity.
However, the ThT effects on additional stress pheno-
types are dependent on HSF-1 and SKN-1, both of
which are stress response transcription factors. This sug-
gests that ThT may lessen Aß-toxicity indirectly via off-
target stress response pathways. Expression of Aß in C.
elegans increases oxidative stress, which occurs prior to
detection of Aß fibril formation [27]. This is consistent
with the idea that the molecular species responsible for
Aß toxicity is pre-fibrillar. Furthermore, single amino
acid substitutions (e.g. Leu17Pro and Met35Cys) blocked
fibril formation in C. elegans but do not reduce toxicity
[28], suggesting that fibrillar-Aß itself is not the toxic
species.
This whole-animal model of Aß1-42 toxicity is well sui-
ted to studies of drug intervention. Assays of paralysis
are rapid (approximately 4 days in total), with a clear
and robust phenotype. PBT2, a drug undergoing clinical
investigation for AD, was found to protect C. elegansagainst Aß1-42 toxicity. This effect is consistent with
neuro-protection reported in AD patients [4] and mouse
AD models [3] and supports the utility of this nematode
model for drug discovery. This model can also provide
useful information on mechanism of action of candidate
drugs. For example, previous cell culture experiments
reported that PBT2 lowered total Aß via up-regulated
matrix metalloproteases [29]. In contrast, we observed
that Aß levels were not affected despite suppression of
Aß-toxicity, suggesting that this animal model has iden-
tified additional modes of drug action.
Conclusions
This new C. elegans model of Aß1-42 toxicity has utility
for screening of compound libraries, serving as a bridge
between high throughput in vitro assays and time and
labour intensive transgenic mouse trials. The turnaround
time of 4 days compared with weeks to months for the
typical mouse study (excluding the months of mainten-
ance and husbandry while the animals reach the appro-
priate age) favours this model as a cost effective method
of identifying lead compounds for more intensive inves-
tigation. This model also provides a useful tool to ex-
plore the mechanism(s) of Aß1-42 toxicity.
Methods
Strains
The strains N2, wild type; CL2120, dvIs14(pCL12(unc-54:
hu-Aß1–42) + pCL26(mtl-2: GFP)), CL2122; dvIs15(mtl-2:
GFP) [28], CL2070, dvIs70(pCL25(hsp16.2:: GFP) + pRF4
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GFP) + pRF4(rol-6(su1006)) [15] were obtained from the
Caenorhabditis Genetics Center. To engineer a full-length
Aß1–42 expressing strain the pCL12 plasmid [10] was
modified by the addition of codons (5’-GAC-CGC-3’) for
residues ASP-ALA between the signal peptide and the
Aß1–42 ORF via a QuikChange Multi Site-Directed Muta-
genesis Kit (Stratagene). The primers used were: 5'-gcac-
cagcaggtaccgacgcggatgcagaattccga, and 5'-tcggaattctgcatcc
gcgtcggtacctgctggtgc. The resulting plasmid, called pCL354
(unc-54:DA-Aß1-42) shown in Additional file 1: Figure S1,
encodes: MHKVLLALFFIFLAPAGTDADAEFRHDSGYEV
HHQKLVFFAEDVGSNKGAIIGLMVGGVVIA, where the
inserted residues are underlined and Aß1-42 sequence
shown in italics. A transgenic strain was generated via
gonad micro-injection and a stable integrant derived fol-
lowing γ-irradiation as previously described [28]. This
strain was then back crossed to wild type four times to
give GMC101, dvIs100 [pCL354(unc-54:DA-Aß1-42) + pCL26
(mtl-2: GFP)]. All strains were cultured at 20°C on NGM
[30] or 8P media [31] with E. coli (strain OP50) as indicated.
On the first day of adulthood (3-days-old), populations were
aged at 20 or 25°C as indicated.Immunoprecipitation
To a ~100 mg liquid-N2 frozen pellet of 5-day-old
GMC101 adults 2:1 (v/w) of 70% formic acid was added
and incubated for 4 hrs at room temperature. The lysate
was centrifuged at 16,500 × g for 15 min, the supernatant
retained and neutralized with 1:20 (v/v) 1 M Tris pH 8.0
and then diluted again 1:10 (v/v) in H20. For immunocap-
ture W0-2 (epitope: Aß5-8) [32] antibody (50 μg) was
bound to 2 mg of dynabeads as per manufacturers instruc-
tions (Invitrogen). Subsequent immunocapture, washing
and elution steps were performed following the manufac-
turer's instructions. The eluted material was vacuum-
centrifuged to dryness then resuspended in 10 μL of 6 M
urea and 5% acetic acid at room temperature for 10 min,
and then desalted and concentrated through a C4 ZipTip
(Millipore) for mass spectrometry.Mass spectrometry
MS measurements were performed on a LTQ-Orbitrap
(Thermo Scientific) operated in the positive ion mode,
with the sample introduced by nano-electrospray from
borosilicate capillaries (New Objective). Typical instru-
mental parameters included; ionisiation spray voltage,
1.5 kV; capillary voltage, 40 V; tube lens voltage, 60 V;
capillary temperature; 300°C; maximum injection time,
100 ms; orbitrap mass resolution, 100000 (at m/z 400);
acquisition time, 1-2 min. Spectra were deconvoluted
and analysed using Qual Browser v.2.0 software
(Thermo Scientific).SELDI-TOF-MS analysis was also performed on TBS
soluble material as previously described [9]. Immuno-
capture was performed using affinity-purified W0-2 (epi-
tope: Aß5-8) [32] antibody coupled to ProteinChip PS10
arrays (Bio-Rad).Immunoblot analysis
For separation of Aß based on peptide hydrophobicity
[33] bis/bicine urea-PAGE analysis was performed as
previously described [9] but modified for a 20 × 20 cm
Protean II xi system (BioRad). Affinity purified 4G8 (epi-
tope: Aß18–22, Signet Laboratories) primary antibody
was used at 1 μg/ml.
For comparison of Aß levels ~1000 adults were col-
lected in S-basal [34] in triplicate, then frozen in liquid-
N2. Samples were then extracted in 3 volumes of urea
buffer (7 M urea, 2 M Thiourea, 4% w/v CHAPS, 1.5%
w/v dithiothreitol and 50 mM Tris pH 8.0) disrupted
via sonication, and then centrifuged at 16,500 × g for
10 min. A 10 μl sample of the supernatant was added
to 3 μl of loading buffer (10% v/v glycerol, 250 mM Tris
pH 8.5, 2% w/v SDS, 0.5 mM EDTA and 0.2 mM Or-
ange-G) and reduced with 1/10 volumes of 0.5 M
dithiothreitol. Samples were then heated at 70°C for
10 min, mixed and centrifuged at 13,000 g for 1 min.
Material was resolved via Tricine-SDS-PAGE (16%/6M
Urea) [35] then transferred to nitrocellulose membranes,
boiled for 3 min (via a microwave oven) in PBS pH 7.4
and blocked for 1 h at room temperature in 0.5% (w/v)
skim milk. Membranes were probed overnight at 4°C
with or 6E10 (epitope: Aß4–9, Sigma) at 1 μg/ml as indi-
cated. Blots were re-probed with anti-α-tubulin (Sigma
T6074, 1:10000) to standardize total protein loading.
Standard enhanced chemiluminescence was then per-
formed [9].Immunohistochemistry
C. elegans were washed in S-basal [34], fixed overnight
in 10% (v/v) Neutral Buffered Formalin (NBF) at 4°C,
embedded in agar (2% w/v in phosphate buffered saline)
blocks and then fixed again in 10% NBF overnight. Fol-
lowing processing of the agar blocks into paraffin, 5 μm
sections were prepared, deparaffinised and treated with
90% formic acid (FA) prior to Aß immunohistochemis-
try with a 1:200 dilution of 1E8 mouse monoclonal
(SmithKline Beecham) antibody (epitope: Aß18–22). Anti-
body binding sites were detected with a peroxidase la-
belled streptavidin biotin system (Dako K0675) with a
3,3’-diaminobenzidine tetrahydrochloride (DAB) chromo-
gen (Dako) resulting in a brown reaction product. Samples
were counter stained with Harris Haematoxylin solution
(Amber Scientific).
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To a frozen pellet of C. elegans 1:1 (w/v) volumes of PBS
(pH7.4) with proteinase inhibitors added (Roche Applied
Science) was added, then disrupted by sonnication using
6 cycles of 6 sec ‘on’, 10 sec ‘off ’ with a 40% duty cycle.
Following centrifugation at 100000 × g for 30 min at 4°C
the soluble fraction was collected and then diluted to
10mg/ml. A single 100 μl injection of 1 mg total protein
into a Superdex 75 10/300 GL gel filtration column was
size excluded in PBS pH7.4 at a flow rate of 0.75 ml/min
using an Agilent 1200 HPLC. Fractions of 1 ml were col-
lected and subsequently analysed by 4-12% BisTris SDS-
PAGE and immunoblot as above using affinity purified
6E10 antibody as above.
Synthesis of X-34 (1,4-bis(3-carboxy-4-
hydroxyphenylethenyl)-benzene)
A modified procedure of Styren et al [12] was used,
where a mixture of 5-formylsalicylic acid (2.2 mmol),
p-xylylenediphosphonic acid tetraethylester (1 mmol) and
potassium tert-butoxide (10 mmol) in anhydrous dimethyl-
formamide (10 mL) was stirred at 40°C for 16 h. The reac-
tion mixture was cooled to room temperature and poured
into ice-water to give yellow precipitate which was isolated
by filtration. The yellow solid was further washed with di-
ethyl ether and dried to give 265 mg of the required prod-
uct. 1H NMR (500 MHz , d6-DMSO): d 7.97 (d, J = 2 Hz,
2H), 7.79 (dd, J = 8.5, 2 Hz, 2H), 7.56 (s, 4H), 7.25 (d, J = 16
Hz, 2H), 7.11 (d, J = 16 Hz, 2H), 6.96 (d, J = 8.5 Hz, 2H).
MS/EI: 403 (M+ 1).
The differential changes in X-34 fluorescence between
freshly refolded and fibrillar Aß1-42 was confirmed by
obtaining emission (excitation: 350 nm) and excitation
(emission: 490 nm) spectra with a Flexstation 3 plate
reader (Molecular Devices) equipped with monochroma-
tors, using an average of 15 reads and an integration
time of 2 seconds (Additional file 4: Figure S3).
Microscopy
Thioflavin T (ThT) staining of 10% Neutral Buffer
Formalin-fixed samples [28] and X-34 in vivo staining in
live C. elegans samples [36] were performed as previ-
ously described, using a Leica DM2500. Immunohisto-
chemistry on whole C. elegans was performed using
6E10 (epitope: Aß4–9) antibody and counter staining of
nuclei using 4',6-diamidino-2-phenylindole (DAPI) was
performed using standard protocols [10].
Paralysis assay
All populations were cultured at 20°C and developmen-
tally synchronized from a 4 h egg-lay. At 64-72 h post
egg-lay (time zero) individuals were shifted to 20°C or
25°C, and body movement assessed over time as indi-
cated. Nematodes were scored as paralysed if they failedto complete full body movement (i.e a point of inflection
traversing the entire body length) either spontaneously
or touch-provoked. Proportion of individuals not paral-
ysed were calculated and confidence intervals determined
without a correction for continuity [37]. Comparisons of
proportions were made using a 2-tailed Z-test. Experi-
ments were replicated as indicated.
Compound effects
PBT-2 (Prana Biotechnology, Australia) was dissolved in
ethanol (<1 ml) and added to molten NGM (at 55°C) at
the concentrations described, no compound controls
included a corresponding volume of ethanol. In addition
all media (control and compound) contained 50 μg/ml
Ampicillin (Sigma) to suppress bacteriological activity.
All media was stored at 4°C and used within one-week.
C. elegans cultures were transferred onto media with
compound as L4 larvae (48 h post egg lay) for 24 h at
20°C. Cultures were then transferred to 25°C as young
adults (time zero) and scored for paralysis as described
above.
Additional files
Additional file 1: Figure S1. A DNA sequence (4982 bp) of plasmid
pCL354(unc-54:DA-Aß1-42). Shown is the DA-insert codons in red and
Aß1-42 ORF in green.
Additional file 2: Figure S2. A SELDI-TOF-MS analysis of TBS lysate
from C. elegans expressing Aß1-42. A peptide species with an average m/
z of 4511.6 Da (775 ppm error) corresponds to Aß1-42 (calculated
average M + H + 4515.1). This estimate is within the typical error
associated with SELDI-TOF-MS. B Epifluorescence micrograph of adult
GMC101 head showing immunolocalization of Aß1-42 (red) with DAPI
stained nuclei (blue).
Additional file 3: Figure S4. Epi-fluorescence micrograph of C. elegans
expressing Aß1-42. A. Live imaging of aggregated Aß using X-34. Dye-
binding aggregates (arrowheads) can be seen throughout the entire
body length. Scale bar = 25μm. B. ThT also binds Aß aggregates
(arrowheads) throughout adult C. elegans.
Additional file 4: Figure S3. Fluorescence properties of X-34. Excitation
(emission wavelength of 490 nm) and emission spectra (using excitation
wavelength of 350nm) were acquired for X-34 in the presence of freshly
refolded (black) and fibrillar Aß1-42 (blue) with a step size of 2 nm. This
analysis indicates a greater than 1000 fold increase in fluorescence
intensity in the presence of fibrillar Aß1-42.
Abbreviations
Aß: amyloid beta peptide; AD: Alzheimer’s disease; 8OHQ: 8-Hydroxy
quinoline; ESI-MS: electrospray ionization-mass spectrometry; ThT: Thioflavin-
T; X-34: 1,4-bis(3-carboxy-4-hydroxyphenylethenyl)-benzene; SDS-
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